secwatch.observer — SEC 8-K summary
======================================

Issuer:     Inhibikase Therapeutics, Inc. (IKT)
CIK:        0001750149
Form:       8-K/A
Filed at:   2024-04-02T23:59:59+00:00
Accession:  0001193125-24-084902
Event type: leadership
Sentiment:  neutral
Materiality: 0.40
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Inhibikase Therapeutics discloses CFO Lees-Rolfe's compensation: $345K salary, 90K option
--------------------------------------------------------------------------------

- Base salary of $345,000 per annum with discretionary annual target bonus of 30% of base.
- Initial stock option for 90,000 shares at $2.16, vesting in three equal annual installments.
- Non-CIC termination severance: 9 months base salary plus COBRA reimbursement for 9 months.
- CIC termination (within 12 months post-change): 12 months base salary lump sum, full equity vesting, one-time Target Bonus.
- Employment Agreement effective April 1, 2024; role as Chief Financial Officer.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1750149/000119312524084902/0001193125-24-084902-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1750149/000119312524084902/d821381d8ka.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-084902

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer